{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:02:39Z","timestamp":1760234559809,"version":"build-2065373602"},"reference-count":100,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019 was held in Morell, Prince Edward Island, 19\u201321 September 2019. Experts in medical oncology, radiation oncology, and surgical oncology who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of anal, colorectal, biliary tract, and gastric cancers, including: radiotherapy and systemic therapy for localized and advanced anal cancer; watch and wait strategy for the management of rectal cancer; role of testing for dihydropyrimidine dehydrogenase (DPD) deficiency prior to commencement of fluoropyrimidine therapy; radiotherapy and systemic therapy in the adjuvant and unresectable settings for biliary tract cancer; and radiotherapy and systemic therapy in the perioperative setting for early-stage gastric cancer.<\/jats:p>","DOI":"10.3390\/curroncol28030185","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T10:30:32Z","timestamp":1622025032000},"page":"1988-2006","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019"],"prefix":"10.3390","volume":"28","author":[{"given":"Joanna","family":"Gotfrit","sequence":"first","affiliation":[{"name":"The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Goodwin","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Asmis","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela J.","family":"Hyde","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Alcindor","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine","family":"Aubin","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM), Montreal, QC H2X 3E4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Berry","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cancer Centre of Southeastern Ontario, Queen\u2019s University, Kingston, ON K7L 5P9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2992-5632","authenticated-orcid":false,"given":"Dominick","family":"Boss\u00e9","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Brown","sequence":"additional","affiliation":[{"name":"PEI Cancer Treatment Centre, Charlottetown, PE C1A 8T5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-3623","authenticated-orcid":false,"given":"Ronald","family":"Burkes","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot","family":"Burnell","sequence":"additional","affiliation":[{"name":"Saint John Regional Hospital, Saint John, NB E2L 4L2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Colwell","sequence":"additional","affiliation":[{"name":"Queen Elizabeth II Health Sciences Centre, Halifax, NS B3H 2Y9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Corbett","sequence":"additional","affiliation":[{"name":"PEI Cancer Treatment Centre, Charlottetown, PE C1A 8T5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Craswell","sequence":"additional","affiliation":[{"name":"Health PEI, Charlottetown, PE C1A 6A5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Daaboul","sequence":"additional","affiliation":[{"name":"Centre Int\u00e9gr\u00e9 de Canc\u00e9rologie de la Mont\u00e9r\u00e9gie, H\u00f4pital Charles LeMoyne, Longueuil, QC J4V 2G9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Doherty","sequence":"additional","affiliation":[{"name":"Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. A. Barry","family":"Fleming","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial University, St. John\u2019s, NL A1C 5S7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Galvis","sequence":"additional","affiliation":[{"name":"Dr Everett Chalmers Regional Hospital, Fredericton, NB E3B 5N5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Goel","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Harb","sequence":"additional","affiliation":[{"name":"The Moncton City Hospital, Moncton, NB E1C 6Z8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin","family":"Jeyakumar","sequence":"additional","affiliation":[{"name":"Queen Elizabeth II Health Sciences Centre, Halifax, NS B3H 2Y9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Jonker","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3782-4463","authenticated-orcid":false,"given":"Michael","family":"Lock","sequence":"additional","affiliation":[{"name":"London Regional Cancer Program, London, ON N6A 5W9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aamer","family":"Mahmud","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cancer Centre of Southeastern Ontario, Queen\u2019s University, Kingston, ON K7L 5P9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick H.","family":"McCrea","sequence":"additional","affiliation":[{"name":"PEI Cancer Treatment Centre, Charlottetown, PE C1A 8T5, Canada"},{"name":"Queen Elizabeth II Health Sciences Centre, Halifax, NS B3H 2Y9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9853-5596","authenticated-orcid":false,"given":"Vimoj","family":"Nair","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Nassabein","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM), Montreal, QC H2X 3E4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0419-3511","authenticated-orcid":false,"given":"Carolyn","family":"Nessim","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5584-3505","authenticated-orcid":false,"given":"Ravi","family":"Ramjeesingh","sequence":"additional","affiliation":[{"name":"Queen Elizabeth II Health Sciences Centre, Halifax, NS B3H 2Y9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Raza","sequence":"additional","affiliation":[{"name":"Dr Everett Chalmers Regional Hospital, Fredericton, NB E3B 5N5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wissam","family":"Saliba","sequence":"additional","affiliation":[{"name":"Cape Breton Cancer Centre, Sydney, NS B1P 1P3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satareh","family":"Samimi","sequence":"additional","affiliation":[{"name":"H\u00f4pital Sacr\u00e9-Coeur de Montr\u00e9al, Montreal, QC H4J 1C5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[{"name":"Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3847-0289","authenticated-orcid":false,"given":"Stephanie","family":"Snow","sequence":"additional","affiliation":[{"name":"Queen Elizabeth II Health Sciences Centre, Halifax, NS B3H 2Y9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1380-5110","authenticated-orcid":false,"given":"Mustapha","family":"Tehf\u00e9","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM), Montreal, QC H2X 3E4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Thirlwell","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Valdes","sequence":"additional","affiliation":[{"name":"Grand River Regional Cancer Centre, Kitchener, ON N2G 1G3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Welch","sequence":"additional","affiliation":[{"name":"London Regional Cancer Program, London, ON N6A 5W9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Vickers","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"ref_1","unstructured":"Statistics Canada (2020). Canadian Cancer Registry, Statistics Canada."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/1097-0142(19940315)73:6<1569::AID-CNCR2820730607>3.0.CO;2-F","article-title":"Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients","volume":"73","author":"Touboul","year":"1994","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: A preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis. Colon Rectum"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups","volume":"15","author":"Bartelink","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","article-title":"EXTRA\u2014A Multicenter Phase II Study of Chemoradiation Using a 5 Day per Week Oral Regimen of Capecitabine and Intravenous Mitomycin C in Anal Cancer","volume":"72","author":"Meadows","year":"2008","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1200\/JCO.2017.35.4_suppl.680","article-title":"Comparison of 5-FU versus capecitabine in combination with mitomycin or cisplatin in the treatment of anal cancer","volume":"35","author":"Yu","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 Trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0360-3016(96)00146-0","article-title":"Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): An Eastern Cooperative Oncology Group study","volume":"35","author":"Martenson","year":"1996","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_13","first-page":"205","article-title":"Dose escalation in chemoradiation for anal cancer: Preliminary results of RTOG 92-08","volume":"2","author":"John","year":"1996","journal-title":"Cancer J. Sci. Am."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.radonc.2011.09.015","article-title":"Node-negative T1\u2013T2 anal cancer: Radiotherapy alone or concomitant chemoradiotherapy?","volume":"102","author":"Zilli","year":"2012","journal-title":"Radiother. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"616","DOI":"10.21037\/jgo.2019.02.06","article-title":"Survival benefits and predictors of use of chemoradiation compared with radiation alone for early stage (T1-T2N0) anal squamous cell carcinoma","volume":"10","author":"Youssef","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Miller, E., Nalin, A., Diaz Pardo, D., Arnett, A., Abushahin, L., Husain, S., Jin, N., Williams, T., and Bazan, J. (2020). Stage I Squamous Cell Carcinoma of the Anus: Is Radiation Therapy Alone Sufficient Treatment?. Cancers, 12.","DOI":"10.3390\/cancers12113248"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10350-007-9154-7","article-title":"Invasive Anal Squamous-Cell Carcinoma in the HIV-Positive Patient: Outcome in the Era of Highly Active Antiretroviral Therapy","volume":"51","author":"Wexler","year":"2008","journal-title":"Dis. Colon Rectum"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.2007.14.2810","article-title":"Human Immunodeficiency Virus\u2013Associated Squamous Cell Cancer of the Anus: Epidemiology and Outcomes in the Highly Active Antiretroviral Therapy Era","volume":"26","author":"Chiao","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_19","unstructured":"National Cancer Institute (2021, March 24). Cancer Stat Facts: Anal Cancer United States 2020, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/anus.html."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"UKCCCR Anal Cancer Trial Working Party (1996). Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet, 348, 1049\u20131054.","DOI":"10.1016\/S0140-6736(96)03409-5"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/DCR.0000000000000827","article-title":"Multimodal Therapy of Squamous Cell Carcinoma of the Anus with Distant Metastasis: A Single-Institution Experience","volume":"60","author":"Evesque","year":"2017","journal-title":"Dis. Colon Rectum"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1634\/theoncologist.2016-0241","article-title":"Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients","volume":"22","author":"Sclafani","year":"2017","journal-title":"Oncologist"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.18632\/oncotarget.2563","article-title":"The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal","volume":"5","author":"Eng","year":"2014","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/COC.0000000000000343","article-title":"Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer","volume":"41","author":"Govindarajan","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-04-0831","article-title":"Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6","volume":"64","author":"Drijfhout","year":"2004","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/COC.0000000000000673","article-title":"Determining Optimal Follow-up for Patients with Anal Cancer Following Chemoradiation","volume":"43","author":"Frazer","year":"2020","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_31","unstructured":"National Comprehensive Cancer Network (2017). NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma, National Comprehensive Cancer Network."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","article-title":"Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): A post-hoc analysis of randomised controlled phase 3 trial","volume":"18","author":"Meadows","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S2468-1253(17)30074-2","article-title":"A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: A systematic review and meta-analysis","volume":"2","author":"Dossa","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S2468-1253(18)30301-7","article-title":"Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): An individual participant data meta-analysis","volume":"3","author":"Chadi","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): An international multicentre registry study","volume":"391","author":"Hilling","year":"2018","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(15)00467-2","article-title":"Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): A propensity-score matched cohort analysis","volume":"17","author":"Renehan","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(15)00120-5","article-title":"High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: A prospective observational study","volume":"16","author":"Appelt","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"djw171","DOI":"10.1093\/jnci\/djw171","article-title":"Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer","volume":"108","author":"Martens","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Smith, J.J., Chow, O.S., Gollub, M.J., Nash, G.M., Temple, L.K., Weiser, M.R., Guillem, J.G., Paty, P.B., Avila, K., and Garcia-Aguilar, J. (2015). Organ Preservation in Rectal Adenocarcinoma: A phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1632-z"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1200\/JCO.2011.37.7176","article-title":"Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer","volume":"29","author":"Maas","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11888-018-0398-5","article-title":"Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer","volume":"14","author":"Bernier","year":"2018","journal-title":"Curr. Colorectal Cancer Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JOP.18.00769","article-title":"Nonsurgical Management of Rectal Cancer","volume":"15","author":"Akce","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"ref_43","unstructured":"NIH (2021, February 17). Trial Evaluating 3-Year Disease Free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-Operative Management, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02008656."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(15)00004-2","article-title":"Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: A multicentre, phase 2 trial","volume":"16","author":"Chow","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study","volume":"19","author":"Hoff","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study","volume":"19","author":"Twelves","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_47","first-page":"23","article-title":"The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology","volume":"12","author":"Diasio","year":"1998","journal-title":"Oncology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/pgs.13.116","article-title":"DPYD IVS14 + 1G > A and 2846A > T genotyping for the prediction of severe fluoropyrimidine-related toxicity: A meta-analysis","volume":"14","author":"Terrazzino","year":"2013","journal-title":"Pharmacogenomics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2013.51.1857","article-title":"Genetic Markers of Toxicity from Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis","volume":"32","author":"Rosmarin","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront Genotyping of DPYD * 2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T > G, c.1236G > A\/HapB3, and c.1601G > A as predictors of severe fluoropyrimidine-associated toxicity: A systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: A prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cpt.685","article-title":"Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity","volume":"102","author":"Nie","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaoncol.2015.5392","article-title":"DPYD Genotyping to Predict Adverse Events Following Treatment with Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial","volume":"2","author":"Boige","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/ijc.29654","article-title":"Clinical validity of aDPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines","volume":"137","author":"Toffoli","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/dju298","article-title":"DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)","volume":"106","author":"Lee","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_57","unstructured":"INESSS (2021, January 15). Traitements A Base de Fluoropyrimidine: GOUVERNEMENT de QUEBEC. Available online: https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Rapports\/Oncologie\/INESSS_DPYD_Traitements.pdf."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1158\/1078-0432.CCR-04-0169","article-title":"Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy","volume":"10","author":"Lecomte","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients with Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma","volume":"34","author":"Hong","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijrobp.2008.03.018","article-title":"Radiation Therapy Is Associated with Improved Survival in the Adjuvant and Definitive Treatment of Intrahepatic Cholangiocarcinoma","volume":"72","author":"Shinohara","year":"2008","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1016\/j.ejca.2014.08.013","article-title":"Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive 9902 phase II randomised study","volume":"50","author":"Phelip","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.radonc.2018.11.015","article-title":"Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma","volume":"132","author":"Brunner","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2007.14.3529","article-title":"Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma","volume":"26","author":"Tse","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/bjs.1800701213","article-title":"Treatment of hilar carcinoma by bile drainage combined with internal radiotherapy using192iridium wire","volume":"70","author":"Fletcher","year":"1983","journal-title":"J. Br. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/bjs.1800821122","article-title":"Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy","volume":"82","author":"Kuvshinoff","year":"1995","journal-title":"J. Br. Surg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0002-9610(97)00203-1","article-title":"Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma","volume":"174","author":"McMasters","year":"1997","journal-title":"Am. J. Surg."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.sla.0000179678.13285.fa","article-title":"Liver Transplantation with Neoadjuvant Chemoradiation is More Effective than Resection for Hilar Cholangiocarcinoma","volume":"242","author":"Rea","year":"2005","journal-title":"Ann. Surg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Kim","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","article-title":"Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: A prospective case-series","volume":"3","author":"Lunsford","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/lt.20512","article-title":"Liver transplantation for incidental cholangiocarcinoma: Analysis of the Canadian experience","volume":"11","author":"Ghali","year":"2005","journal-title":"Liver Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11605-007-0335-4","article-title":"Outcomes Analysis for 280 Patients with Cholangiocarcinoma Treated with Liver Transplantation Over an 18-year Period","volume":"12","author":"Becker","year":"2008","journal-title":"J. Gastrointest. Surg."},{"key":"ref_72","first-page":"873","article-title":"Radiation therapy in the treatment of cholangiocarcinoma","volume":"20","author":"Czito","year":"2006","journal-title":"Oncology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0360-3016(77)90186-9","article-title":"The role of radiation therapy in cancer of the extra-hepatic biliary system: An analysis of thirteen patients and a review of the literature of the effectiveness of surgery, chemotherapy and radiotherapy","volume":"2","author":"Kopelson","year":"1977","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1016\/j.ijrobp.2010.12.019","article-title":"Role of Adjuvant Chemoradiotherapy for Resected Extrahepatic Biliary Tract Cancer","volume":"81","author":"Kim","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2006.11.048","article-title":"Adjuvant Concurrent Chemoradiation for Adenocarcinoma of the Distal Common Bile Duct","volume":"68","author":"Hughes","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9610(05)80612-9","article-title":"Management of Proximal cholangiocarcinomas by surgical resection and radiotherapy","volume":"159","author":"Cameron","year":"1990","journal-title":"Am. J. Surg."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1055\/s-2008-1040466","article-title":"Results of radiation therapy in carcinoma of the proximal bile duct (Klatskin tumor)","volume":"10","author":"Gonzalez","year":"1990","journal-title":"Semin. Liver Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00268-002-6434-1","article-title":"Results of Postoperative Radiotherapy for Resectable Hilar Cholangiocarcinoma","volume":"27","author":"Gerhards","year":"2003","journal-title":"World J. Surg."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/00000658-199506000-00017","article-title":"Perihilar Cholangiocarcinoma Postoperative Radiotherapy Does Not Improve Survival","volume":"221","author":"Pitt","year":"1995","journal-title":"Ann. Surg."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma","volume":"33","author":"Guthrie","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"JAMA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study","volume":"37","author":"Edeline","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"J. Br. Surg."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2\/3 trial","volume":"393","author":"Homann","year":"2019","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2016.69.7276","article-title":"It Is Time to Stop Using Epirubicin to Treat Any Patient with Gastroesophageal Adenocarcinoma","volume":"35","author":"Elimova","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative Chemotherapy Compared with Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/jso.23009","article-title":"Neoadjuvant chemotherapy with FOLFOX: Improved outcomes in Chinese patients with locally advanced gastric cancer","volume":"105","author":"Li","year":"2011","journal-title":"J. Surg. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/bjs.9632","article-title":"Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer","volume":"101","author":"Ahn","year":"2014","journal-title":"J. Br. Surg."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): An international, open-label, randomised phase 3 trial","volume":"19","author":"Cats","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/jso.23795","article-title":"Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: A meta-analysis of randomized controlled trials","volume":"111","author":"Dai","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","volume":"345","author":"Macdonald","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial","volume":"379","author":"Bang","year":"2012","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2017.04.027","article-title":"Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial","volume":"81","author":"Stahl","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/bjs.10663","article-title":"Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer","volume":"105","author":"Polom","year":"2018","journal-title":"J. Br. Surg."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","article-title":"Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial","volume":"3","author":"Smyth","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/SLA.0000000000002803","article-title":"Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II\/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study","volume":"270","author":"Choi","year":"2019","journal-title":"Ann. Surg."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/3\/185\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:07:55Z","timestamp":1760162875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/3\/185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":100,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["curroncol28030185"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28030185","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2021,5,26]]}}}